Impact of Carbonyl Reductase 3 Genotype Status on Echocardiographic Measurements of Cardiomyopathy in Breast Cancer Patients Treated with Anthracyclines

The aim of this prospective study is to examine whether the CBR3 V244M genotype status is associated with changes in 3 sensitive echocardiographic measures of cardiomyopathy in breast cancer patients being treated with standard dose anthracyclines.

Study Number: 

I 219812

Principal Investigator: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail